Lung Therapeutics
Toby Maher, M.D. Ph.D. is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles and Professor of Interstitial Lung Disease at the National Heart and Lung Institute at Imperial College London, UK, and Honorary Physician at Royal Brompton Hospital, London.
His research interests include clinical trials, biomarker discovery, the lung microbiome and host immune response in the pathogenesis of IPF, and clinical trials in fibrotic lung disease. He is an associate editor for the American Journal of Respiratory and Critical Care Medicine. He has authored over 260 papers and book chapters on IPF.
This person is not in the org chart
This person is not in any offices
Lung Therapeutics
Lung Therapeutics, Inc. is a clinical-stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs.